用法用量 |
IVF(rate: 60 minutes)
NSCLC
1.Non–small cell lung cancer, resectable, neoadjuvant and adjuvant therapy(Non-squamous or squamous tumor histologies)
≥30 kg:1500 mg once every 3 weeks (in combination with platinum-containing chemotherapy) for 4 cycles, followed by surgery, followed by 1500 mg once every 4 weeks (as a single agent) until disease progression that precludes definitive surgery, recurrence, or unacceptable toxicity or a maximum of 12 cycles after surgery
<30 kg: 20 mg/kg once every 3 weeks (in combination with platinum-containing chemotherapy) for 4 cycles, followed by surgery, followed by 20 mg/kg once every 4 weeks (as a single agent) until disease progression that precludes definitive surgery, recurrence, or unacceptable toxicity or a maximum of 12 cycles after surgery
2.Non–small cell lung cancer, stage 3, unresectable
≥30 kg: 10 mg/kg once every 2 weeks or 1500 mg once every 4 weeks; continue until disease progression or unacceptable toxicity or a maximum of 12 months
<30 kg: 10 mg/kg once every 2 weeks; continue until disease progression or unacceptable toxicity or a maximum of 12 months
ES-SCLC
Patients >30 kg: 1,500 mg once every 3 weeks (in combination with etoposide and either carboplatin or cisplatin) for 4 cycles, followed by 1,500 mg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity
Patients ≤30 kg: 20 mg/kg once every 3 weeks (in combination with etoposide and either carboplatin or cisplatin) for 4 cycles, followed by 20 mg/kg once every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity.
Biliary tract cancer, locally advanced or metastatic
≥30 kg: 1500 mg once every 3 weeks (in combination with gemcitabine and cisplatin) for up to 8 cycles, followed by 1500 mg once every 4 weeks as a single agent until disease progression or unacceptable toxicity
<30 kg: 20 mg/kg once every 3 weeks (in combination with gemcitabine and cisplatin) for up to 8 cycles, followed by 20 mg/kg once every 4 weeks as a single agent until disease progression or unacceptable toxicity. |
副作用 |
Cough, fatigue, pneumonitis, upper respiratory tract infection, dyspnea |